DCGOHealthcare · Medical Care FacilitiesDCGO Stock Forecast: DocGo, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering DocGo, Inc. hold a median 12-month price target of $1.75 — +170.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 1 Aug 2026 — in the upper half.
DCGO stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores DocGo, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (99): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (14): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own DocGo, Inc. — and when they’d sell — is the membership.
DCGO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on DCGO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +170.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Mar 2026 | Canaccord Genuity | Maintains | Hold | $1.50 → $1.00 |
| 17 Mar 2026 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 17 Mar 2026 | Needham | Reiterates | Buy | — |
| 17 Mar 2026 | Stifel | Maintains | Buy | — |
| 12 Nov 2025 | Canaccord Genuity | Maintains | Hold | — |
| 21 Aug 2025 | Canaccord Genuity | Maintains | Hold | — |
| 12 May 2025 | Canaccord Genuity | Downgrade | Hold | — |
| 9 May 2025 | Needham | Maintains | Buy | — |
| 8 Apr 2025 | Needham | Reiterates | Buy | — |
| 28 Feb 2025 | Needham | Maintains | Buy | — |
| 28 Feb 2025 | Stifel | Maintains | Buy | — |
| 16 Jan 2025 | Needham | Reiterates | Buy | — |
| 20 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 20 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 8 Aug 2024 | Needham | Reiterates | Buy | — |
| 9 May 2024 | BTIG | Maintains | Buy | — |
| 9 May 2024 | Canaccord Genuity | Maintains | Buy | — |
| 9 May 2024 | Cantor Fitzgerald | Maintains | Overweight | — |
| 9 May 2024 | Needham | Maintains | Buy | — |
| 30 Apr 2024 | Stifel | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
DCGO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
DocGo, Inc. (DCGO) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 8.5×
- Price / sales
- 0.2×
- Price / book
- 0.5×
- EV / EBITDA
- −0.5×
Cheaper than 62% of US stocks
Cheaper than 92% of US stocks
Cheaper than 84% of US stocks
Cheaper than 64% of US stocks
- Revenue growth (YoY)
- −21.3%
- Earnings growth (YoY)
- −21.3%
- Gross margin
- 31.6%
- Operating margin
- −24.8%
- Net margin
- −62.2%
Higher than 11% of US stocks
Higher than 19% of US stocks
Higher than 38% of US stocks
Higher than 22% of US stocks
Higher than 8% of US stocks
- Return on equity
- −97.8%
- Return on assets
- −18.3%
- Dividend yield
- —
Higher than 13% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
DCGO vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DCGO appears on the weeks it earns a place.
Frequently asked questions about DCGO stock
What is the DCGO stock price forecast for 2026-2027?
The 5 Wall Street analysts covering DocGo, Inc. have a median 12-month price target of $1.75, with estimates ranging from $1 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is DCGO stock a buy right now?
Of the 5 analysts covering DocGo, Inc., 2 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks DocGo, Inc. 59 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank DCGO?
As at 1 Aug 2026, DocGo, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (99 of 100).
Will DCGO stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +170.0% from the last close, and Ticker Nerd's factor model ranks DocGo, Inc. 59 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the DCGO stock forecast for 2030?
No analyst covering DocGo, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DCGO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $3 over the next 12 months.
How has DCGO stock performed over the past year?
DocGo, Inc. returned -51.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does DocGo, Inc. do?
DocGo Inc. is a dynamic healthcare service provider that focuses on mobile and integrated medical care solutions.
About DocGo, Inc.
DocGo Inc. is a dynamic healthcare service provider that focuses on mobile and integrated medical care solutions. The company operates by delivering non-emergency medical services directly to patients, breaking traditional barriers to healthcare access. A key feature of DocGo's business is its use of technology to streamline healthcare delivery, including real-time tracking of medical transportation and remote patient monitoring. This approach not only enhances patient convenience but also optimizes the efficiency of medical service delivery. DocGo's services are critical across various sectors, particularly in underserved communities where access to timely medical care is challenging. As an essential player in the healthcare sector, DocGo supports hospital systems and emergency services by alleviating the burden on traditional healthcare facilities, thereby contributing to the overall enhancement of healthcare infrastructure. Through its innovative model, DocGo is making significant strides in transforming healthcare accessibility and service delivery in the modern era.
CEO Mr. Lee Bienstock · 2,537 employees · United States · https://docgo.com